QoL · adults aged ≥ 65 years
1 finding from 1 review
Level of emerging personal care needs (approved for higher level of care)*** · adults aged ≥ 65 years
1 finding from 1 review
Living arrangements (transferred to residential care) · adults aged ≥ 65 years
1 finding from 1 review
Cost effectiveness*** Total aggregated costs for home‐ and healthcare (emergency department and unplanned hospital admissions) · adults aged ≥ 65 years
1 finding from 1 review
Intervention not reported
Time to wound healing · patients aged 18 years or over with primary perianal abscess
1 finding from 1 review
Intervention not reported
Wound pain at initial dressing change Scale: VAS (high score= worse pain) · patients aged 18 years or over with primary perianal abscess
1 finding from 1 review
Intervention not reported
Wound pain over 2 weeks Scale: VAS (high score= worse pain) · patients aged 18 years or over with primary perianal abscess
1 finding from 1 review
Neonatal tetanus deaths ‐ 1 dose · women aged between 13 and 45 years.
Tetanus toxoid showed no clear difference in neonatal tetanus deaths ‐ 1 dose compared with influenza vaccine (low certainty).
1 finding from 1 review
Neonatal tetanus deaths ‐ 2 or 3 doses · women aged between 13 and 45 years.
Tetanus toxoid probably leads to lower neonatal tetanus deaths ‐ 2 or 3 doses compared with influenza vaccine (moderate certainty).
1 finding from 1 review
All causes of deaths ‐ 1 dose · women aged between 13 and 45 years.
Tetanus toxoid showed no clear difference in all causes of deaths ‐ 1 dose compared with influenza vaccine (low certainty).
1 finding from 1 review
All causes of deaths ‐ 2 or 3 doses · women aged between 13 and 45 years.
Tetanus toxoid probably leads to lower all causes of deaths ‐ 2 or 3 doses compared with influenza vaccine (moderate certainty).
1 finding from 1 review
Neonatal tetanus cases ‐ Any dose · women aged between 13 and 45 years.
Tetanus toxoid probably leads to lower neonatal tetanus cases ‐ Any dose compared with influenza vaccine (moderate certainty).
1 finding from 1 review
Intervention not reported
Medicine use · vulnerable population: senior 65 years of age or older
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall use of medicines · vulnerable population: senior 65 years of age or older
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Use of medicines for symptomatic conditions · vulnerable population: senior 65 years of age or older
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Use of medicines for asymptomatic conditions · vulnerable population: senior 65 years of age or older
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Cost · vulnerable population: senior 65 years of age or older
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Patient perspective · vulnerable population: senior 65 years of age or older
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Insurer perspective (expenditures on medicines) · vulnerable population: senior 65 years of age or older
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Insurer perspective (expenditures on health care) · vulnerable population: senior 65 years of age or older
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found